A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”

June 26, 2026Dermatology and TherapyOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To address concerns about the comparability of responder rates in trials comparing tralokinumab and lebrikizumab.
Clarified study methodologies of ECZTRA 1, ECZTRA 2, ADvocate 1, and ADvocate 2 trials.
Highlighted the definition of week 16 responder as per IGA and EASI-75 criteria.
Discussed washout periods of topical medications in the trials.
Confirmed that week 52 efficacy is comparable among the trials for the specified responder definition.
Explained that differences in trial designs potentially affected the week 16 response outcomes.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Letter responses clarify efficacy comparisons of tralokinumab and lebrikizumab in atopic dermatitis, suggesting methodological insights.

No takes yet. Share an insight, caveat, or question.

Augustin et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share